Genetic sequencing company Illumina is facing challenges, including a $9.8 million settlement with the Department of Justice and sanctions in China. Despite a stock drop of over 21%, CEO Jacob Thaysen remains optimistic, citing growth opportunities in partnering with pharmaceutical companies. Illumina is looking to expand into preventative care, specifically cancer screenings, for future growth. China’s ban on Illumina’s imports, due to the tariff war, has impacted the company’s earnings significantly, with Thaysen working to reverse the decision. Despite facing local competition in China, Illumina sees the market as an appealing one to remain in. Analysts are waiting for progress on Illumina’s return to growth, with Jefferies maintaining a Hold rating until key uncertainties are resolved.

Read more at Yahoo Finance: Will big Pharma come to its rescue? Its CEO thinks so.